PIWIL2 and in situ carcinoma: In breast cancer, several studies showed an upregulation of PIWIL2 in tumor tissue with highest levels in invasive carcinomas as compared to benign or in situ carcinomas, but no significant differences in patient outcome between PIWIL2 low and high-expressing groups [12, 156, 157, 169].